Aurinia Pharmaceuticals (AUP) Reaches New 12-Month High at $10.07

Shares of Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$10.07 and last traded at C$9.79, with a volume of 115876 shares traded. The stock had previously closed at C$9.41.

Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last issued its quarterly earnings results on Thursday, November 8th. The company reported C($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.23) by C($0.05). The firm had revenue of C$0.49 million for the quarter, compared to analyst estimates of C$0.09 million. As a group, analysts expect that Aurinia Pharmaceuticals Inc will post -0.679999976826412 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://transcriptdaily.com/2019/01/12/aurinia-pharmaceuticals-aup-reaches-new-12-month-high-at-10-07.html.

Aurinia Pharmaceuticals Company Profile (TSE:AUP)

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Why do companies engage in swaps?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply